Name: **Didier BREYER, PhD**

Nationality and date of birth: Belgian, 23 December 1962

Participation in COST Action FP0905:

Describe your participation : MC substitute, Member of WG2

ESR at the time of starting the Action: ~~Yes~~ / Not

Contact data:

Address: Scientific Institute of Public Health
Division of Biosafety and Biotechnology (SBB)
Rue J. Wytsmanstraat 14
B-1050 Brussels, Belgium

Email: didier.breyer@wiv-isp.be
Phone: +32 (0)2 642 53 54
Fax: +32 (0)2 642 52 92

Research area and species (key words):

Biosafety, risk assessment, risk management, environmental impact assessment, GMO regulation, guidance, Cartagena Protocol

All species

I received my Ph.D. in Biology from the University of Liège (Belgium) in 1989 and conducted academic research activities for 6 years in the field of molecular biology applied to micro-organisms. Since 1995 I have been working as senior scientist in the Division of Biosafety and Biotechnology (SBB) of the Scientific Institute of Public Health (Brussels, Belgium). I am involved mainly in the scientific evaluation and administrative follow-up of biosafety dossiers, providing scientific support to the Belgian Biosafety Advisory Council and the Belgian Competent Authorities in particular regarding the environmental release of GMOs and the placing on the market of GMOs and derived products. I am active in various european and international working groups involved in biosafety-related matters. I have been appointed since 2001 as Belgian Focal Point for the Biosafety Clearing-House of the Cartagena Protocol on Biosafety. I am also working in the development and management of web-based information exchange mechanisms in the field of biosafety (in particular the "Belgian Biosafety Server" - http://www.biosafety.be).

CURRICULUM VITAE

Present position

Senior scientist at the Division of Biosafety and Biotechnology (SBB) of the Scientific Institute of Public Health.
Main activities and responsibilities:

- Supervising the scientific expertise and the secretariat in the framework of the activities of the Belgian Biosafety Advisory Council.
- Drafting a wide variety of texts (legislative and policy proposals, background papers, advices, scientific publications and recommendations) for competent authorities and partners involved in biosafety matters.
- Scientific evaluation and administrative follow-up of regulatory dossiers relating to the use of genetically modified and/or pathogenic organisms in contained facilities, to the environmental release of GMOs and to the placing on the EU market of GMOs and derived products.
- National Focal Point for the "Biosafety Clearing-House" (BCH) of the Cartagena Protocol on Biosafety.
- Scientific support to the Belgian delegation at EU level (Council, Commission) and in various international Fora (United Nations, OECD, CEN) within the framework of the negotiation or implementation of EU legislation and international agreements relating to biosafety and GMO.
- Participation in research projects.
- Public information in the field of biosafety, in particular via Internet.

Education/Professional Career

year	Position /Felowship etc..
1990 - 1993	Researcher (Assistant). University of Liège, Belgium. Basic and applied research activities in the laboratory, using molecular and cell biology techniques. Teaching to undergraduates.
1984 - 1989	PhD Thesis. University of Liège, Belgium. Basic research in the field of molecular biology contributing to a better understanding of regulation of gene expression in micro-organisms.
1980 - 1984	Master in Botanical Sciences. University of Liège, Belgium.

Others

-

-

Research Projects (relevant to Action)

Years	Description
2005-2009	**Co-Extra - GM and non-GM supply chains : their co-existence and traceability**. The main objective of this FP6 European project is to supply the tools required to implement co-existence and traceability with a view to the co-existence in supply chains of GM, conventional and organic products.

Selected Publications and Communications (relevant to Action)

- Breyer D., Goossens M., Herman P. and Sneyers M. 2010. *Biosafety considerations associated with molecular farming in genetically modified plants.* Accepted for publication in J. Medic. Plants Res.

- Breyer D., Roosens N., Berben G., Taverniers I, Van den Bulcke M. and Sneyers M. 2009. European project Co-Extra: GM and non-GM supply chains: their co-existence and traceability. Labinfo, N°3, November 2009.

- Breyer D., Herman P., Brandenburger A., Gheysen G., Remaut E., Soumillion P., Van Doorsselaere J., Custers R., Pauwels K., Sneyers M. and Reheul D. 2009. *Should novel organisms developed using oligonucleotide-mediated mutagenesis be excluded from the EU Regulation ?* ISB News Report, Nov 09, 9.

- Breyer D., Herman P., Brandenburger A., Gheysen G., Remaut E., Soumillion P., Van Doorsselaere J., Custers R., Pauwels K., Sneyers M. and Reheul D. 2009. *Genetic modification through oligonucleotide-mediated mutagenesis. A GMO regulatory challenge?* Environ. Biosafety Res., 8, 57-64.

- Collard J-M, Breyer D., Renckens S., Sneyers M., Van Haver E., Van Vaerenbergh B., and Moens W. 2009*. Biosafety in Biotechnology.* Encyclopedia of Life Support Systems (EOLSS), UNESCO-EOLSS Publishers Co Ltd.

- Breyer D., Daubresse P. and Sneyers M. 2007. *Bringing scientists to the people - the Co-Extra website*. Biotechnol. J., 2(9), 1081-1085.

RESEARCH INSTITUTE

Description

The Scientific Institute of Public Health (IPH) is a scientific institute of the federal Belgian State. Its main mission is scientific research in view of support of health policy. It provides also expertise and public service in the field of public health.

The IPH plays an important role as part of the Belgian representation at the level of the European Union and some international organisations as the World Health Organisation (WHO), the Organisation for Economic Cooperation and Development (OECD) and the Council of Europe, whenever scientific and/or technical aspect of public health are involved.

The main activities of the IPH are related to the following fields:

- Surveillance of communicable diseases
- Surveillance of non-communicable diseases
- Verification of federal product norms (e.g. food, pharmaceuticals, vaccines)
- Risk assessment (e.g. chemical products, genetically modified organisms (GMO's)
- Environment and health

- Management of biological resources (collections of strains of microorganisms)

The Institute has a staff of more than 500 people, one third of which are scientific personnel.

Although the IPH is a public service of the federal government, it disposes of legal personality, what facilitates rapid and flexible execution of research contracts for third parties.

Infrastructure

Located in Brussels, Belgium.